Novel cancer immunotherapy agents with survival benefit: recent successes and next steps

被引:506
作者
Sharma, Padmanee [1 ,2 ,3 ]
Wagner, Klaus [4 ]
Wolchok, Jedd D. [3 ,5 ]
Allison, James P. [3 ,6 ,7 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA
[3] Mem Sloan Kettering Canc Ctr, Ludwig Ctr Canc Immunotherapy, New York, NY 10065 USA
[4] Univ Texas MD Anderson Canc Ctr, Div Med, Houston, TX 77030 USA
[5] Mem Sloan Kettering Canc Ctr, Div Melanoma Med Oncol, New York, NY 10065 USA
[6] Mem Sloan Kettering Canc Ctr, Dept Immunol, New York, NY 10065 USA
[7] Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10065 USA
关键词
PHASE-II TRIAL; IFN-GAMMA; COMBINATION IMMUNOTHERAPY; ANTITUMOR IMMUNITY; CLINICAL-TRIALS; PEPTIDE VACCINE; T-CELLS; MELANOMA; CTLA-4; BLOCKADE;
D O I
10.1038/nrc3153
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The US Food and Drug Administration (FDA) recently approved two novel immunotherapy agents, sipuleucel-T and ipilimumab, which showed a survival benefit for patients with metastatic prostate cancer and melanoma, respectively. The mechanisms by which these agents provide clinical benefit are not completely understood. However, knowledge of these mechanisms will be crucial for probing human immune responses and tumour biology in order to understand what distinguishes responders from non-responders. The following next steps are necessary: first, the development of immune-monitoring strategies for the identification of relevant biomarkers; second, the establishment of guidelines for the assessment of clinical end points; and third, the evaluation of combination therapy strategies to improve clinical benefit.
引用
收藏
页码:805 / 812
页数:8
相关论文
共 61 条
[1]  
[Anonymous], 2010, J CLIN ONCOL S
[2]   Toward the harmonization of immune monitoring in clinical trials: Quo vadis? [J].
Britten, C. M. ;
Janetzki, S. ;
van der Burg, S. H. ;
Gouttefangeas, C. ;
Hoos, A. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2008, 57 (03) :285-288
[3]  
BURNET FM, 1970, PROG EXP TUMOR RES, V13, P1
[4]  
BURNET FM, 1967, LANCET, V1, P1171
[5]   Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma [J].
Camacho, Luis H. ;
Antonia, Scott ;
Sosman, Jeffrey ;
Kirkwood, John M. ;
Gajewski, Thomas F. ;
Redman, Bruce ;
Pavlov, Dmitri ;
Bulanhagui, Cecile ;
Bozon, Viviana A. ;
Gomez-Navarro, Jesus ;
Ribas, Antoni .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (07) :1075-1081
[6]   Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial [J].
Carthon, Bradley C. ;
Wolchok, Jedd D. ;
Yuan, Jianda ;
Kamat, Ashish ;
Tang, Derek S. Ng ;
Sun, Jingjing ;
Ku, Geoffrey ;
Troncoso, Patricia ;
Logothetis, Christopher J. ;
Allison, James P. ;
Sharma, Padmanee .
CLINICAL CANCER RESEARCH, 2010, 16 (10) :2861-2871
[7]   Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues [J].
Chen, Hong ;
Liakou, Chrysoula I. ;
Kamat, Ashish ;
Pettaway, Curtis ;
Ward, John F. ;
Tang, Derek Ng ;
Sun, Jingjing ;
Jungbluth, Achim A. ;
Troncoso, Patricia ;
Logothetis, Christopher ;
Sharma, Padmanee .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (08) :2729-2734
[8]   Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents [J].
Dancey, Janet E. ;
Dobbin, Kevin K. ;
Groshen, Susan ;
Jessup, J. Milburn ;
Hruszkewycz, Andrew H. ;
Koehler, Maria ;
Parchment, Ralph ;
Ratain, Mark J. ;
Shankar, Lalitha K. ;
Stadler, Walter M. ;
True, Lawrence D. ;
Gravell, Amy ;
Grever, Michael R. .
CLINICAL CANCER RESEARCH, 2010, 16 (06) :1745-1755
[9]  
Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514
[10]   IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression [J].
Dunn, GP ;
Sheehan, KCF ;
Old, LJ ;
Schreiber, RD .
CANCER RESEARCH, 2005, 65 (08) :3447-3453